Plain-English translation of NCT05354375 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of immunotherapy called PSMA-targeted CAR-T cell therapy for men with castration-resistant prostate cancer—a form of the disease that no longer responds to standard hormone treatments. The treatment involves taking your immune cells, modifying them in the laboratory to recognize and attack prostate cancer cells, and then infusing them back into your body. This medication is designed to help your immune system fight the cancer more effectively.
Standard treatments stop working for many men with advanced prostate cancer, leaving few options. This trial exists to see whether training immune cells to specifically target prostate cancer cells could offer a new, more effective treatment path for men in this situation.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy to prepare your body for the new immune cells, then receive an infusion of the modified cells on Day 0. You'll also receive additional injections to support the immune cells for several weeks. During the first 6 months, you'll have frequent blood tests and imaging scans to check how well the treatment is working and monitor for side effects. After that, you'll continue with quarterly check-ups for 2 years, then annual phone follow-ups and surveys for up to 5 years total to track your long-term health and any recurrence.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Collaborators
Xuzhou Medical University
Enrollment target
~20 participants
Started
December 2022
Primary completion
November 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Sex
Male only
Last updated on clinicaltrials.gov in April 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hailong Li, M.D/Ph.D
The Affiliated Hospital of Xuzhou Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.